undamentalytics Newsletter

Intrexon Corp: insider trades

Director, 10% owner at 6 companies we cover. 11 open-market purchases and 2 sales not made under a pre-set plan, reported from January 14, 2011 to April 3, 2019.

Would copying Intrexon Corp’s purchases have beaten the S&P 500?

Too few purchases to judge. Only 4 purchases have 12 months of prices after the report; we judge insiders once they have 20. The figures below can swing a long way on a handful of trades. Buying each purchase the day after it was reported, an equal amount each, and holding it 12 months or until they reported a sale would have turned $10,000 on January 18, 2011 into $6,693 by November 2, 2026, −2.5% a year. The copy held shares only 17% of the time, so the fair comparison is the S&P 500 on those same days with Treasury bills otherwise: $13,138, +1.8% a year (the S&P 500 held throughout made $76,945, +13.8% a year). Beta against the index was 0.28. Twelve months after each report, the average purchase was −23.8% against the S&P 500 (median −25.7%), and 0% beat it. Measured from the trade date, the insider’s own timing, the average was −21.3%.

With 296 insiders tested, some will look skilled or unskilled by chance alone: when we replaced each insider’s stocks with random companies bought on the same days, about 5.7 cleared the bar ahead and 23.3 behind. One record on its own proves little.

$0$25.0k$50.0k$75.0k 20112013201520172019202120232025 $76.9k$13.1k$6.7k
Copying Intrexon CorpS&P 500, same days investedS&P 500, held throughout $10,000 copying Intrexon Corp’s open-market purchases from January 18, 2011, before costs and taxes, marked weekly. Each purchase gets the same starting stake, bought at the close of the first trading day after the report and sold 12 months later or the day after a reported sale of that stock; uninvested money earns the Treasury bill rate. “Same days invested” holds the S&P 500 only on the days the copy held shares, Treasury bills otherwise.
Return a year, copying
−2.5%
S&P 500, same days invested
+1.8% (held throughout +13.8%)
Time in shares
17%
Sharpe ratio (S&P 500)
−0.05 (0.75)
Biggest drop (S&P 500)
−66% (−34%)
Market sensitivity (beta)
0.28
Purchases copied
4

Trade by trade

Intrexon Corp: trades against the S&P 500 afterwards
MeasuredTrades countedAverage vs S&P 500MedianWent the right wayYearst-statisticp-valueEvidence
Purchases, 3 months after the report 4 −6.3% −5.4% 50% 2 — — Not enough years
Purchases, 6 months after the report 4 −6.7% −7.8% 50% 2 — — Not enough years
Purchases, 12 months after the report 4 −23.8% −25.7% 0% 2 — — Not enough years
Purchases, 12 months after the trade 3 −21.3% −22.6% 0% 2 — — Not enough years
Sales, 3 months after the report 0 — — — — — — Not enough years
Sales, 12 months after the report 0 — — — — — — Not enough years
Sales, 12 months after the trade 0 — — — — — — Not enough years

“Average vs S&P 500” is the stock’s return including dividends minus the index’s over the same dates, from the close on the first trading day after the report, or from the close on the trade date. Only windows that have finished are counted. For sales, a negative figure means the stock lagged after it was sold, so selling was the right call (green). “Went the right way” is the share of purchases that beat the index, or of sales that trailed it. The t-statistic uses one average per year of reports, because one person’s trades bunch into the same stock and weeks, and needs trades in at least four different years; the p-value comes from the t distribution with that number of years (with four years, a t of 2 has p = 0.14). “Some evidence” means p under 5%, “strong evidence” p under 1% over at least six years.

Companies traded

CompanyTitle on the latest filingPurchasesSalesFirst reportLatest report
Alaunos Therapeutics, Inc. TCRT —50January 14, 2011February 10, 2015
Oragenics Inc OGEN —30August 2, 2012July 5, 2016
Theriva Biologics, Inc. TOVX —11December 19, 2013April 3, 2019
Armata Pharmaceuticals, Inc. ARMP —10March 18, 2015March 18, 2015
Aquabounty Technologies Inc AQB —10January 19, 2018January 19, 2018
Ocugen, Inc. OCGN —01January 15, 2019January 15, 2019

Trades and what followed

Moves are against the S&P 500; green means the trade went the insider’s way.

ReportedTradedCompanyTradeValue3 months after report12 months after report12 months after trade
April 3, 2019April 1, 2019 TOVX Sale $98,837 not yetnot yetnot yet
January 15, 2019January 11, 2019 OCGN Sale $158,772 not yetnot yetnot yet
January 19, 2018January 17, 2018 AQB Purchase $4,999,998 not yetnot yetnot yet
July 5, 2016June 30, 2016 OGEN Purchase $1,175,938 not yetnot yetnot yet
March 18, 2015March 16, 2015 ARMP Purchase $2,369,697 not yetnot yetnot yet
February 10, 2015February 9, 2015 TCRT Purchase $12,600,000 +1.0%−30.7%−28.7%
December 19, 2013December 17, 2013 TOVX Purchase $2,500,000 not yetnot yetnot yet
October 31, 2013October 29, 2013 TCRT Purchase $10,000,000 not yetnot yetnot yet
October 2, 2013September 30, 2013 OGEN Purchase $7,945,530 not yetnot yetnot yet
August 2, 2012July 31, 2012 OGEN Purchase $1,286,332 not yetnot yetnot yet
August 25, 2011August 23, 2011 TCRT Purchase $191,087 −11.7%−27.1%−22.6%
August 9, 2011August 5, 2011 TCRT Purchase $4,042,234 −24.3%−24.3%not yet
January 14, 2011January 12, 2011 TCRT Purchase $11,645,928 +9.9%−13.2%−12.7%

Open-market purchases and sales of at least $10,000 in companies we cover, from SEC Form 4 filings; sales made under a pre-set Rule 10b5-1 plan are not shown. “Not yet” means the window has not finished or the share price was under $5 at entry. These are the shares’ moves after each trade: they say nothing about why Intrexon Corp traded and do not suggest the use of non-public information. How every insider compares · the insider trading backtest.